Rare disease outcome assessment under EU HTA and joint clinical assessment | Becaris Publishing

#RareDisease outcome assessment under #EUHTA and #JointClinicalAssessment | Becaris Publishing becarispublishing.com/digital-cont...

Join us for our next webinar, 𝗝𝗖𝗔 𝗦𝘂𝗰𝗰𝗲𝘀𝘀: 𝗧𝗵𝗲 𝗘𝘃𝗶𝗱𝗲𝗻𝗰𝗲-𝗕𝗮𝘀𝗲𝗱 𝗦𝗶𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝗔𝗱𝘃𝗮𝗻𝘁𝗮𝗴𝗲!

Preparing for the EU #JointClinicalAssessment is about more than just gathering evidence.

www.linkedin.com/events/jcasu...

Quote and potrait picture: 'Since the beginning of 2025, EU countries have been working more closely together to assess new drugs in the European health technology assessment (EU-HTA) process. The aim is to provide member states with a scientific assessment of the available evidence to inform decisions in their healthcare systems.' - Regina Skavron, Head of the Methodology and Coordination of European HTA Division, 9/2025

First EU HTAs with IQWiG involvement launched! 🚀

The Institute is involved in four #oncology drug assessments as an assessor or co-assessor.

www.iqwig.de/en/presse/pr...

#EUHTA #JCA #JointClinicalAssessment

Joint Clinical Assessment Rules on Health Tech Assessment Now in Effect: New Era for Patient Access to Innovation The EU’s health technology assessment framework, effective from January 2025, improves patient access to new cancer medicines and advanced therapies.

It's a new era for patient access to health innovation. The EU Commission's Joint Clinical Assessment Rules on HTA are now in effect. Learn about what this era heralds: ow.ly/ImgU50UFFBI #JCA #jointclinicalassessment #patientaccess PharmSky HEOR

New consortium of HTA agencies to support implementation of EU HTA regulation

Two weeks after the European Union’s #HealthTechnologyAssessmentRegulation came into effect, the formation of a new consortium marks a significant milestone in its implementation.

#EUHTAR #hta #healthtechnologyassessment #healthpolicy #jointclinicalassessment

becarispublishing.com/digital-cont...